|Start Date / Time||September 23, 2020 at 9:00 AM|
|End Date / Time||September 23, 2020 at 10:00 AM|
|Presenter Name||Julie Bejoy, Ph.D. and Megan Rasmussen|
|Status||This meeting has already occurred|
Megan Rasmussen - “MCL-1 regulation of mitochondrial dynamics and homeostasis in iPSC-derived cardiomyocytes”
MCL-1 is a well-characterized inhibitor of cell death that has also been shown to be a regulator of mitochondrial dynamics in human induced pluripotent stem cells (hiPSCs). We used hiPSC-derived cardiomyocytes (hiPSC-CMs) to uncover whether MCL-1 is necessary for cardiac function and survival. BH3 mimetics targeting MCL-1 are promising anti-tumor therapeutics. We show that BH3 mimetics targeting MCL-1 cause abnormal mitochondrial network morphology and cardiac performance. Our results emphasize the need for a more complete molecular understanding of MCL-1’s mechanism of action in human cardiomyocytes, as it may reveal new approaches to prevent potential cardiac toxicities associated with chemotherapeutic inhibition of MCL-1.
Julie Bejoy, Ph.D. - “Incorporation of Urine-Derived Stem Cells into Injured Human Kidney Organoids”
Because of their renal origin, viable cells isolated from the urinary pellet called urine-derived stem cells are a potential candidate for development of stem cell-based therapies for acute kidney injury. We induced injury in human induced pluripotent stem cell-derived kidney organoids using nephrotoxic drugs. We then evaluated the therapeutic impact and localization of labeled urine-derived stem cells when added to the injured organoids.